MOTS-c
Mitochondrial Open Reading Frame of the 12S rRNA Type-c
Regulatory Status
Not FDA-approved. Emerging research peptide. Limited compounding availability.
FDA · Updated Mar 2026
Not licensed by MHRA. Research chemical only.
MHRA · Updated Mar 2026
Not scheduled by TGA. Limited availability.
TGA · Updated Mar 2026
Not currently on WADA prohibited list.
WADA · Updated Jan 2026
What Is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. It was first identified and characterised in 2015 by Dr. Changhan David Lee and colleagues at the University of Southern California (USC), representing one of the first mitochondria-derived peptides (MDPs) shown to have significant metabolic signalling functions [1].
Unlike most peptides used in research, which are synthetic analogues of pituitary or hypothalamic hormones, MOTS-c originates from mitochondrial DNA — specifically from the 12S rRNA gene. This discovery challenged the conventional understanding that mitochondrial DNA primarily encodes proteins involved in the electron transport chain, revealing a previously unrecognised role for mitochondria as endocrine signalling organelles [2].
MOTS-c has been described as an “exercise mimetic” due to its apparent ability to activate metabolic pathways typically stimulated by physical exercise, particularly the AMP-activated protein kinase (AMPK) pathway. Research suggests that MOTS-c levels decline with age, leading to hypotheses about its potential role in age-related metabolic dysfunction [3].
MOTS-c is not approved by the FDA, MHRA, TGA, or any regulatory agency for human therapeutic use. It remains an emerging research peptide with limited availability. Individuals considering MOTS-c should consult a qualified healthcare provider and understand the current state of the evidence.
Mechanism of Action
Research has identified several key mechanistic pathways through which MOTS-c may exert its metabolic effects:
AMPK activation. The primary mechanism described in the literature is MOTS-c’s activation of the AMP-activated protein kinase (AMPK) signalling cascade. AMPK is often called the “metabolic master switch” as it regulates cellular energy homeostasis. Studies indicate that MOTS-c may activate AMPK by inhibiting the folate cycle and de novo purine biosynthesis pathway, leading to accumulation of the AMPK activator AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) [1][4].
Folate-methionine cycle modulation. Research suggests that MOTS-c targets the folate cycle, specifically inhibiting the transformation of 5-methyl-tetrahydrofolate. This metabolic disruption leads to downstream effects on one-carbon metabolism and nucleotide synthesis, with AMPK activation as a consequent metabolic adaptation [4].
Nuclear translocation. A significant finding by Kim et al. (2018) demonstrated that under metabolic stress, MOTS-c translocates from the cytoplasm to the nucleus, where it interacts with nuclear DNA to regulate gene expression related to antioxidant defence and metabolic adaptation [5]. This represents a novel form of mitochondrial-nuclear communication.
Insulin signalling enhancement. Animal studies suggest that MOTS-c may improve insulin sensitivity through AMPK-mediated enhancement of glucose uptake in skeletal muscle, independent of the insulin receptor signalling pathway [1]. This parallels the effects of exercise on muscle glucose utilisation.
Research and Evidence
Metabolic Regulation and Insulin Sensitivity
The foundational research on MOTS-c centres on its metabolic effects. Lee et al. (2015) demonstrated that MOTS-c administration in mice prevented age-dependent and high-fat-diet-induced insulin resistance [1]. Treated mice showed improved glucose tolerance, reduced fat accumulation, and enhanced insulin sensitivity compared to controls.
Subsequent research confirmed these findings and extended them to models of obesity and type 2 diabetes. Studies indicate that MOTS-c may enhance skeletal muscle glucose uptake through AMPK-dependent mechanisms, functioning in a manner analogous to exercise-induced metabolic improvements [4]. These findings have generated significant interest in MOTS-c as a potential target for metabolic disease research.
Exercise Mimetic Properties
One of the most compelling aspects of MOTS-c research is its characterisation as an exercise mimetic. Studies have shown that exercise increases circulating MOTS-c levels in humans, and that the peptide’s molecular effects overlap significantly with the metabolic adaptations produced by physical activity [6].
Research by Reynolds et al. (2021) demonstrated that MOTS-c administration improved exercise capacity in mouse models, enhancing endurance performance and promoting favourable metabolic adaptations in skeletal muscle [7]. The peptide appeared to enhance fatty acid oxidation and mitochondrial function, effects typically associated with endurance training.
Ageing and Longevity
A growing body of research has examined MOTS-c in the context of ageing. Studies indicate that circulating MOTS-c levels decline with age in both rodents and humans [3]. This age-related decline correlates with the development of insulin resistance, sarcopenia, and other metabolic features of ageing.
Research by Kim et al. (2019) reported that MOTS-c administration in aged mice improved physical capacity, metabolic parameters, and several biomarkers of ageing [8]. These findings have positioned MOTS-c as a molecule of interest in geroscience research, though the translation to human anti-ageing applications remains speculative.
Body Composition
Animal studies suggest that MOTS-c may favourably influence body composition. Research in diet-induced obesity models has demonstrated that MOTS-c administration reduced fat mass accumulation and preserved lean mass [1][7]. These effects are hypothesised to result from enhanced fatty acid oxidation and improved mitochondrial efficiency in metabolic tissues.
Dosage and Administration
Important: The following information reflects dosages reported in animal research and early community protocols. MOTS-c is not an approved medication, and no human dosing guidelines exist. The translation of animal dosing to human protocols involves significant uncertainty. Always consult a qualified healthcare provider before considering any peptide protocol.
Common Research and Community-Reported Protocols
- Subcutaneous injection: 5-10 mg per week, often divided into daily or every-other-day administrations. Community protocols typically reference doses of 0.5-1.5 mg per day. These dosages are extrapolated from animal research and have not been validated in human clinical trials.
- Timing: Some community protocols reference administration in the morning or pre-exercise, based on the rationale of aligning with metabolic activity patterns, though optimal timing has not been established.
Reconstitution
MOTS-c is supplied as a lyophilised powder requiring reconstitution with bacteriostatic water. Due to its larger molecular weight (2174.69 Da), careful reconstitution and proper storage at 2-8 degrees Celsius are essential. Use the reconstitution calculator for precise mixing guidance.
Cycling
Community protocols often reference cycles of 4-8 weeks. The optimal duration and cycling pattern have not been established through clinical research. Some protocols suggest continuous low-dose use under medical supervision, though this approach lacks clinical validation.
Side Effects and Safety
The safety profile of MOTS-c in humans has not been established through controlled clinical trials. As a relatively recently discovered endogenous peptide, the available safety data is limited primarily to animal studies.
Observed in animal studies: MOTS-c has demonstrated a favourable safety profile in rodent studies at the doses tested. No significant organ toxicity or adverse effects have been reported in published preclinical research [1][8].
Community-reported side effects (anecdotal, extremely limited data):
- Injection site reactions (redness, mild discomfort)
- Transient nausea
- Mild fatigue
- Hypoglycaemia-like symptoms (lightheadedness, hunger), particularly if used with other glucose-lowering agents
Potential concerns and unknowns:
- Human safety and pharmacokinetic data are essentially absent
- As an endogenous peptide involved in fundamental metabolic signalling, the long-term effects of exogenous supplementation are unknown
- Interactions with diabetes medications, particularly metformin (which also acts through AMPK), have not been characterised
- Effects on cancer metabolism are unclear — while AMPK activation is generally considered tumour-suppressive, the full implications are not understood
- Effects during pregnancy and lactation are unknown; use should be avoided
- The quality and purity of commercially available MOTS-c may vary significantly given its relative novelty
Frequently Asked Questions
What makes MOTS-c different from other peptides?
MOTS-c is unique in that it is encoded by mitochondrial DNA rather than nuclear DNA. This makes it one of the first identified mitochondria-derived peptides with systemic signalling functions. Most other peptides in the research space (such as BPC-157 or growth hormone secretagogues) are synthetic analogues of nuclear-encoded proteins. MOTS-c’s mitochondrial origin represents a fundamentally different biological pathway [2].
Is MOTS-c really an “exercise mimetic”?
Research suggests that MOTS-c activates many of the same molecular pathways stimulated by exercise, particularly AMPK signalling and enhanced fatty acid oxidation [6][7]. However, the term “exercise mimetic” should be interpreted cautiously. While MOTS-c may recapitulate some metabolic effects of exercise, physical activity produces a far broader range of physiological benefits — cardiovascular, musculoskeletal, neurological, and psychological — that cannot be replicated by any single molecule.
Does MOTS-c decline with age?
Research indicates that circulating MOTS-c levels decrease with age in both rodent models and human studies [3]. This decline has been correlated with age-related metabolic dysfunction, including reduced insulin sensitivity and increased adiposity. However, whether this decline is a cause or consequence of metabolic ageing remains an active area of investigation.
Can MOTS-c be combined with metformin?
Both MOTS-c and metformin act through AMPK-related pathways, raising theoretical concerns about additive or synergistic effects on glucose metabolism. No studies have evaluated this combination. Individuals taking metformin or other diabetes medications should exercise particular caution and consult their healthcare provider before considering MOTS-c [4].
How new is MOTS-c research?
MOTS-c was first described in the scientific literature in 2015 [1], making it one of the newer peptides in the research space. While the initial findings are promising, the total body of evidence is substantially smaller than for peptides that have been studied for decades. Human clinical trial data is essentially absent, and much of the current understanding is derived from animal models.
References
References
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.
- Kim SJ, et al. Mitochondrial-derived peptides: small molecules with a big role in regulating metabolism. Cell Metabolism. 2017;25(4):499-513.
- D'Souza RF, et al. Circulatory MOTS-c levels are reduced with aging and increase after exercise in humans. Physiological Reports. 2020;8(13):e14349.
- Lee C, et al. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radical Biology and Medicine. 2016;100:182-187.
- Kim SJ, et al. MOTS-c: an equal opportunity insulin sensitizer. Journal of Molecular Medicine. 2018;96(9):869-872.
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470.
- Reynolds JC, et al. Exercise-induced MOTS-c enhances physical capacity and metabolic fitness. Cell Metabolism. 2021;33(11):2247-2259.
- Kim SJ, et al. The mitochondrial-derived peptide MOTS-c improves healthspan in aged mice. Aging Cell. 2019;18(5):e12994.
- Zempo H, et al. MOTS-c and exercise capacity: a study of genetic variants in Japanese adults. Aging. 2020;12(3):1857-1872.
- Yin X, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacological Research. 2022;175:105987.
Continue Reading